Treatment of patients infected with hepatitis C virus and presenting extrahepatic manifestations

Brazilian Journal of Infectious Diseases

Volumn 11, Issue SUPPL. 1, 2007, Pages 56-60

  Tengan, Fátima Mitiko ^a   Barone, Antonio Alci ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AUTOANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB;

ARTHRITIS; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DRUG CLEARANCE; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; LICHEN PLANUS; LYMPHOMA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PORPHYRIA CUTANEA TARDA; SJOEGREN SYNDROME; THYROID DISEASE;

EID: 36949034474     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Zuckerman E., Keren D., Slobodin G., et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27: 2172-8.
2. Mazzaro C., Zorat F., Comar C., et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 2003;30:1775-81.
3. Alric L., Plaisier E., Thebault S., et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43:617-23.
4. Cacoub R, Saadoun D., Limal N., et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005;52:911-5.
5. Mazzaro C., Zorat F., Caizzi M., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005;42:632-8.
6. Cid M.C., Hernandez-Rodriguez J., Robert J., et al. Interferon-alpha may exacerbate cryoglobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic, activity. Arthritis Rheum 1999;42:1051-5.
7. Suzuki H., Takei T., Tsuji H., Nishikawa T. Membranoproliferative glomerulonephritis and demyelinating neuropathy caused by type II mixed cryoglobulinemia associated with HCV infection. Intern Med 2000; 39:397-400.
8. Ferri C., Giuggioli D., Cazzato M., et al. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 2003;21:S78-S84.
9. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
10. Vallisa D., Bernuzzi P., Arcaini L., et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23:468-73.
11. Hermine O., Lefrere F., Bronowicki J.P., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
12. Kelaidi C., Rollot E, Park S., et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004;18:1711-6.
13. Zuckerman E., Zuckerman T., Sahar D., Streichman S. Attias therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001;97:1555-9.
14. Gisbert J.P., Garcia-Bucy L., Pajares J.M., Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005;21:653-62.
15. Hainsworth J.D., Litchy S., Burris H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7.
16. Somer B.G., Tsai D.E., Downs L., et al. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003;49:394-8.
17. Ramos-Casals M., Lopez-Guillermo A., Brito-Zeron P., et al. Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis C virus infection. Lupus 2004;13:969-71.
18. Muratori L., Lenzi M., Cataleta M., et al. Interferon therapy in liver/ kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994;21:199-203.
19. Garcia-Buey L., Garcia-Monzon C., Rodriguez S., et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-7.
20. Doffoel-Hantz V., Loustaud-Ratti V., Ramos-Casals M., et al. Evolution of Sjogren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin. Rev Med Interne 2005;26:88-94.
21. Fernandez L, Castellano G., Salamanca R.D., et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 2003;38(3):314-9.
22. Jessner W., Der-Petrossian M., Christiansen L., et al. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology 2002;36(5):1301-2.
23. Doutre M.S., Beylot C., Couzigou R, et al. Lichen planus and virus C hepatitis: disappearance of the lichen under interferon alfa therapy. Dermatology 1992;184:229.
24. Boccia S., Gamberini S., Dalla Libera M., et al. Lichen planus and interferon therapy for hepatitis C. Gastroenterology 1993; 105:1921-2.
25. Barreca T., Corsini G, Franceschini R., et al. Lichen planus induced by interferon- alpha-2a therapy for chronic active hepatitis C.Eur. J. Gastroenterol. Hepatol 1995;7:367-8.
26. Nagao Y., Sata M., Ide T., et al. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest 1996;26:1171-4.
27. Schlesinger T.E., Camisa C., Gay J.D., Bergfeld W.F. Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection. J Am Acad Dermatol 1997;36:1023-5.
28. Dalekos G.N., Christodoulou D., Kistis K.G., et al. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998;10:933-9.
29. Protzer U., Ochsendorf F.R., Leopolder-Ochsendorf A., Holtermuller K.H. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993;104:903-5.
30. Di Bisceglie A.M., Martin P., Kassianides C., et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321(22):1506-10.
31. Lisker-Melman M., Bisceglie A.D., Usala S., et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992;102(6):2155-60.
32. Marazuela M., Garcia-Buey L., Gonzalez-Fernandez B., et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44(6):635-42.
33. Deutsch M., Dourakis S., Manesis E., et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26(1):206-10.
34. Mazziotti G., Sorvillo F., Stornaiuolo G., et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002;25(7):624-30.
35. Willson R.A. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997;92(1):3-17.
36. Lecoub A., Hernandez C., Simó R., et al. Glucose abnormalities are na independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroentreol 2007;102:1-7.
37. Johnson R.J., Gretch D.R., Yamabe H., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.
38. Diego J.M., Roth D. Treatment of hepatitis C infection in patients with renale disease. Curr Opin Nephrol Hypert 1988;7:557.
39. Misiani R., Bellavita P., Baio P., et al. Successful treatment ofHCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant 1999; 14:1558-60.
40. Mazzaro C., Panarello G, Carniello S., et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000;32:708-15.
41. Dammacco F., Sansonno D., Han J.H., et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-43.
42. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998;54:650-71.
43. Bombardieri S., Ferri C., Paleologo G., et al. Prolonged plasma exchange in the treatment of renal involvement in essential mixed cryoglobulinemia. Int J Artif Organs 1983;6(Suppl. 1):47-50.
44. Ferri C., Moriconi L., Gremignai G., et al. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986;43:246-53.
45. Madore F., Lazarus J.M., Brady H.R. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996;7:367-86.
46. Jefferson J.A., Johnson R.J. Treatment of hepatitis C-associated glomerular disease. Semin Nephrol 2000;20:286-92.
47. Reed M.J., Alexander G.J., Thiru S., Smith K.G. Hepatitis C-associated glomerulonephritis - a novel therapeutic approach. Nephrol Dial Transplant 2001;16:869-71.
48. Scelsa S.N., Herskovitz S., Reichler B. Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia. Muscle Nerve 1998;21(11):1526-9.
49. Ramos-Casals M., Trejo O., Garcia-Carrasco M., Font J. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology [Oxford] 2003; 42(7):818-28.